Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD-3: Vercirnon Extension in Crohn's Disease
NCT01318993Phase 3Terminated
- Sponsor
- GSK
- Start
- Apr 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of vercirnon in Crohn's disease, sponsored by GSK. Started Apr 2011; status: terminated.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01318993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01318993.